A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies

Journal of the National Cancer Institute

Volumn 112, Issue 5, 2020, Pages 466-479

  Ten Haaf, Kevin ^a   Bastani, Mehrad ^b   Cao, Pianpian ^c   Jeon, Jihyoun ^c   Toumazis, Iakovos ^b   Han, Summer S ^b   Plevritis, Sylvia K ^b   Blom, Erik F ^a   Kong, Chung Yin ^d,e   Tammemägi, Martin C ^f   Feuer, Eric J ^g   Meza, Rafael ^c   De Koning, Harry J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BROCK UNIVERSITY   (Canada)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; LIFE EXPECTANCY; LUNG CANCER; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; EARLY CANCER DIAGNOSIS; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; RISK ASSESSMENT; RISK FACTORS; SMOKING;

EID: 85076108327     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djz164     Document Type: Article

References (41)

1. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5): 395-409.
2. Moyer VA, on behalf of the U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330-338.
3. Tammema€gi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368(8):728-736.
4. Raji OY, Duffy SW, Agbaje OF, et al. Predictive accuracy of the Liverpool lung project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. Ann Intern Med. 2012;157(4):242-250.
5. ten Haaf K, Jeon J, Tammema€gi MC, et al. Risk prediction models for selection of lung cancer screening candidates: a retrospective validation study. PLoS Med. 2017;14(4):e1002277.
6. Katki HA, Kovalchik SA, Petito LC, et al. Implications of nine risk prediction models for selecting ever-smokers for computed tomography lung cancer screening. Ann Intern Med. 2018;169(1):10.
7. Wood DE, Kazerooni EA, Baum SL, et al. Lung cancer screening, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(4):412-441.
8. de Koning HJ, van der Aalst CM, ten Haaf K, Oudkerk M. PL02.05 Effects of volume CT lung cancer screening: mortality results of the NELSON randomised-controlled population based trial. J Thorac Oncol. 2018;13(10):S185.
9. Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. Lancet Oncol. 2017;18(12):e754-e766.
10. Katki HA, Kovalchik SA, Berg CD, et al. Development and validation of risk models to select ever-smokers for CT lung cancer screening. JAMA. 2016; 315(21):2300-2311.
11. Tammemagi MC, Schmidt H, Martel S, et al. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. Lancet Oncol. 2017;18(11):1523-1531.
12. Field JK, Duffy SW, Baldwin DR, et al. The UK lung cancer screening trial: A pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess. 2016;20(40):1-146.
13. Holford TR, Levy DT, McKay LA, et al. Patterns of birth cohort-specific smoking histories, 1965-2009. Am J Prev Med. 2014;46(2):e31-e37.
14. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351-364.
15. Kumar V, Cohen JT, van Klaveren D, et al. Risk-targeted lung cancer screening: a cost-effectiveness analysis. Ann Intern Med. 2018;168(3):161-169.
16. Crosbie PA, Balata H, Evison M, et al. Implementing lung cancer screening: baseline results from a community-based "Lung Health Check" pilot in de-prived areas of Manchester. Thorax. 2019;74(4):405-409.
17. Cheung LC, Katki HA, Chaturvedi AK, et al. Preventing lung cancer mortality by computed tomography screening: the effect of risk-based versus U.S. Preventive Services Task Force eligibility criteria, 2005-2015. Ann Intern Med. 2018;168(3):229-232.
18. Duffy SW, Field JK, Allgood PC, et al. Translation of research results to simple estimates of the likely effect of a lung cancer screening programme in the United Kingdom. Br J Cancer. 2014;110(7):1834.
19. de Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160(5):311-320.
20. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst. 2003;95(6):470-478.
21. Meza R, Hazelton WD, Colditz GA, et al. Analysis of lung cancer incidence in the Nurses' Health and the Health Professionals' Follow-Up studies using a multistage carcinogenesis model. Cancer Causes Control. 2008;19(3): 317-328.
22. Jeon J, Holford TR, Levy DT, et al. Smoking and lung cancer mortality in the United States from 2015 to 2065: a comparative modeling approach. Ann Intern Med. 2018;169(10):684.
23. Tam J, Levy DT, Jeon J, et al. Projecting the effects of tobacco control policies in the USA through microsimulation: a study protocol. BMJ Open. 2018;8(3): e019169.
24. Tammema€giMC, Church TR, Hocking WG, et al. Evaluation ofthe lung cancer risks at which to screen ever-and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med. 2014;11(12):e1001764.
25. ten Haaf K, de Koning HJ. Should never-smokers at increased risk for lung cancer be screened? J Thorac Oncol. 2015;10(9):1285-1291.
26. Landy R, Cheung LC, Berg CD, et al. Contemporary implications of U.S. Preventive Services Task Force and risk-based guidelines for lung cancer screening eligibility in the United States. Ann Intern Med. 2019;171(5):384-386.
27. Caverly TJ, Cao P, Hayward RA, et al. Identifying patients for whom lung cancer screening is preference-sensitive: a microsimulation study. Ann Intern Med. 2018;169(1):1-9.
28. Criss SD, Sheehan DF, Palazzo L, et al. Population impact of lung cancer screening in the United States: projections from a microsimulation model. PLoS Med. 2018;15(2):e1002506.
29. Han SS, Erdogan SA, Toumazis I, et al. Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model. Cancer Causes Control. 2017;28(9):947-958.
30. Lin RS, Plevritis SK. Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model. Cancer Causes Control. 2012;23(1):175-185.
31. McMahon PM, Kong CY, Johnson BE, et al. Chapter 9: the MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal. 2012;32(suppl 1): S117-S124.
32. ten Haaf K, van Rosmalen J, de Koning HJ. Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials. Cancer Epidemiol Biomarkers Prev. 2015;24(1):154.
33. Meza R, ten Haaf K, Kong CY, et al. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer 2014;120(11):1713-1724.
34. Cressman S, Peacock SJ, Tammema€gi MC, et al. The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency. J Thorac Oncol. 2017;12(8):1210-1222. https://doi.org/10.1016/j.jtho.2017.04.021.
35. Han SS, ten Haaf K, Hazelton WD, et al. The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. Int J Cancer. 2017; 140(11):2436-2443.
36. Hazelton WD, Jeon J, Meza R, et al. Chapter 8: the FHCRC lung cancer model. Risk Anal. 2012;32(suppl 1):S99-S116.
37. Schultz FW, Boer R, de Koning HJ. Chapter 7: description of MISCAN-lung, the Erasmus MC lung cancer microsimulation model for evaluating cancer control interventions. Risk Anal. 2012;32(suppl 1):S85-S98.
38. Wang Y, Midthun DE, Wampfler JA, et al. Trends in the proportion of patients with lung cancer meeting screening criteria. JAMA. 2015;313(8): 853-855.
39. Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014;371(19):1793-1802.
40. ten Haaf K, Tammemagi MC, Bondy SJ, et al. Performance and cost-effectiveness of computed tomography lung cancer screening scenarios in a population-based setting: a microsimulation modeling analysis in Ontario, Canada. PLoS Med. 2017;14(2):e1002225.
41. Manuel DG, Perez R, Sanmartin C, et al. Measuring burden of unhealthy behaviours using a multivariable predictive approach: life expectancy lost in Canada attributable to smoking, alcohol, physical inactivity, and diet. PLoS Med. 2016;13(8):e1002082.